Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
1 clinical trials · Condition
◉ Watch Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
| Record | Firm | Date |
|---|---|---|
| An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations. (NCT04671849) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2020-12-21 |
Track Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion automatically
Every clearance here is in the API, with alerts when new ones post.